Stem Cells: Model, Target, & Therapy
Tuesday, 23 June 2020
Stem cells can drive clinical development in a diversity of ways. Stem cells can help identify new therapeutics through disease modeling, drug screening, and personalized medicine. Endogenous stem cells can be the targets of therapeutics, which can stimulate regeneration in vivo. Finally, stem cells or stem cell-derived products can be the therapeutic themselves, delivered to patients to replace or repair damaged tissues. The ISSCR’s Workshop on Clinical Translation will showcase speakers from academia and industry who will discuss various approaches to develop cellular therapies in this translationally-focused program. This year’s workshop explores the broad ways that stem cells are advancing pre-clinical research and clinical trials in three sessions:
- Modeling Stem Cells for Discovery
- Endogenous Stem Cells as Targets
- Stem Cells as Drugs in Clinical Trials
The Workshop on Clinical Translation is a full-day program designed for scientists, physicians, physician-scientists, and those interested in the latest clinical applications of stem cell research. A renowned panel of speakers will cover a range of topics from pre-clinical modeling to ongoing clinical trials.
Date: 23
Time: TBD
Where: Online
Registration: Included with ISSCR 2020 Annual Meeting registration
Tentative Speakers + Topics
WELCOME | OPENING REMARKS
[ Welcome to the Workshop on Clinical Translation. ]

[Program Committee]
Lee Rubin, PhD
Harvard University, USA
SESSION 1 | MODELING STEM CELLS FOR DISCOVERY
[ Disease modeling, therapeutic screening, and advanced approaches including the genetics of disease and personalized medicine. ]
[Program Committee + Moderator]
Ricardo Dolmetsch, PhD
Novartis, USA
Giorgia Quadrato, PhD
University of Southern California, Keck School of Medicine, USA
Clifford Woolf, MD, PhD
Boston Children's Hospital, USA
Ronald Li, PhD
Karolinska Institutet, Sweden/Hong Kong
NovoHeart, Canada
Ajamete Kaykas, PhD
Insitro, USA
SESSION 2 | ENDOGENOUS STEM CELLS AS TARGETS
[ Drugs that target endogenous stem cells for therapeutic purposes.]
[Program Committee + Moderator]
Chee-Yeun Chung, PhD
Yumanity, USA
Domenico Accili, MD
Columbia Universiry, USA
Hua Lin, PhD
Forkhead Biotherapeutics, USA
Alison McGuigan, PhD
University of Toronto, Canada
Albert Edge, PhD
Massachusetts Eye and Ear, USA; Decibel Therapeutics, USA
SESSION 3 | STEM CELLS AS DRUGS
[ What is at the cutting edge and what is the future of cell and gene therapy. ]
[Program Committee + Moderator]
Jerome Ritz, MD
Dana Farber Cancer Institute, USA
David Williams, MD
Boston Children's Hospital, USA
Agnete Kirkeby, PhD
University of Copenhagen, Denmark
Lund University, Sweden
Sonja Schrepfer, MD, PhD
University of California, San Francisco, USA
[ All sessions will conclude with a panel discussion between the speakers and the moderator. ]
WRAP UP | CLOSING REMARKS
[ Where the clinical translation of stem cells is and where it is going. ]
[Program Committee]
Stacie Weninger, PhD
F-Prime Capital, USA
Who Should Attend?
This program is designed for scientists, physicians, physician-scientists, and those interested in the latest clinical applications of stem cell research.
How to Register
Your registration is included in your ISSCR 2020 Annual Meeting registration.